Dupilumab, marketed as Dupixent, is a biologic medication [1]. It is a monoclonal antibody that targets key proteins in inflammatory pathways [2].
What makes Dupixent a biologic?
Biologics are medical products made from living organisms or their components [3]. Dupixent is produced using recombinant DNA technology in a mammalian cell line [4]. This process involves genetically modifying cells to produce specific proteins, which are then purified [4]. Unlike small molecule drugs, which are chemically synthesized and have well-defined structures, biologics are complex molecules produced by living systems and are not typically characterized by a simple chemical formula [3].
How does Dupixent work?
Dupixent targets the alpha subunit of the interleukin-4 receptor (IL-4Rα) [2]. This subunit is shared by the IL-4 and IL-13 receptor complexes [2]. By blocking these receptors, Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines that play a significant role in Type 2 inflammation [2]. This mechanism is central to its therapeutic effect in conditions driven by this type of inflammation [2].
What conditions is Dupixent approved for?
Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis in adults and children [5]. It is also indicated for the treatment of moderate-to-severe asthma in patients aged 6 years and older, as an add-on maintenance treatment [5]. Additionally, Dupixent is used for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults [5]. It is also indicated for eosinophilic esophagitis in patients aged 12 years and older, weighing 88 lbs (40 kg) or more, and for prurigo nodularis in adults [5].
When does Dupixent's patent expire?
Patent expiry dates for biologics like Dupixent can be complex due to multiple patents covering different aspects of the drug, including manufacturing processes and formulations [6]. Information on specific patent expiry dates and potential biosimilar entry can be found on resources like DrugPatentWatch.com [6].
Can biosimilars be developed for Dupixent?
The development of biosimilars for complex biologic drugs like Dupixent is possible once relevant patents expire and regulatory pathways are met [7]. Biosimilars are highly similar to their reference biologic, with no clinically meaningful differences in terms of safety, purity, and potency [8].
What are the alternatives to Dupixent?
Treatment options for the conditions Dupixent treats vary. For atopic dermatitis, alternatives include topical corticosteroids, calcineurin inhibitors, Janus kinase (JAK) inhibitors, and other systemic immunosuppressants [5]. For asthma, inhaled corticosteroids, long-acting beta-agonists, and other biologics targeting different inflammatory pathways are available [5]. For chronic rhinosinusitis with nasal polyposis, treatment may involve nasal corticosteroids, oral corticosteroids, and surgery [5].
Sources:
[1] https://www.drugpatentwatch.com/en/drug/dupilumab
[2] https://www.regeneron.com/products/dupixent
[3] https://www.fda.gov/vaccines-blood-biologics/biologics/what-biologic-product
[4] https://www. Dupixent.com/
[5] https://www.dupixent.com/Dupixent-treatment-efficacy
[6] https://www.drugpatentwatch.com/
[7] https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-and-indicating-reference-products
[8] https://www.fda.gov/drugs/biosimilars